These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8646527)

  • 1. How to really heal with crystals.
    Nat Struct Biol; 1996 Jun; 3(6):483-4. PubMed ID: 8646527
    [No Abstract]   [Full Text] [Related]  

  • 2. Serine protease inhibitors (SERPINS): where mechanism meets medicine.
    Rubin H
    Nat Med; 1996 Jun; 2(6):632-3. PubMed ID: 8640547
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.
    Aertgeerts K; De Bondt HL; De Ranter CJ; Declerck PJ
    Nat Struct Biol; 1995 Oct; 2(10):891-7. PubMed ID: 7552714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration.
    Kataoka H; Itoh H; Koono M
    Pathol Int; 2002 Feb; 52(2):89-102. PubMed ID: 11940213
    [No Abstract]   [Full Text] [Related]  

  • 5. [Structure and function of marinostatin, a serine protease inhibitor].
    Taichi M; Nishiuchi Y
    Seikagaku; 2010 Nov; 82(11):1032-6. PubMed ID: 21226332
    [No Abstract]   [Full Text] [Related]  

  • 6. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?
    De Taeye B; Gils A; Declerck PJ
    Thromb Haemost; 2004 Nov; 92(5):898-924. PubMed ID: 15543316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro PAI-1 inhibitory activity of oxalamide derivatives.
    Jain MR; Shetty S; Chakrabarti G; Pandya V; Sharma A; Parmar B; Srivastava S; Raviya M; Soni H; Patel PR
    Eur J Med Chem; 2008 Apr; 43(4):880-4. PubMed ID: 17664030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pyrrolin-2-one derivatives synthesized by a new practical method as inhibitors of plasminogen activator inhibitor-1 (PAI-1).
    Miyazaki H; Miyake T; Terakawa Y; Ohmizu H; Ogiku T; Ohtani A
    Bioorg Med Chem Lett; 2010 Jan; 20(2):546-8. PubMed ID: 19969458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adipocyte and hemostatic balance in obesity: studies of PAI-1.
    Loskutoff DJ; Samad F
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):1-6. PubMed ID: 9445248
    [No Abstract]   [Full Text] [Related]  

  • 10. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.
    Magdolen V; Arroyo de Prada N; Sperl S; Muehlenweg B; Luther T; Wilhelm OG; Magdolen U; Graeff H; Reuning U; Schmitt M
    Adv Exp Med Biol; 2000; 477():331-41. PubMed ID: 10849761
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B; Verbeke K; Compernolle G; Biesemans W; Gils A; Declerck PJ
    Biochem Biophys Res Commun; 2003 Aug; 307(3):529-34. PubMed ID: 12893254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinase inhibitors: another new fold.
    Grütter MG
    Structure; 1994 Jul; 2(7):575-6. PubMed ID: 7922036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of scaffolding in standard mechanism serine proteinase inhibitors.
    Kelly CA; Laskowski M; Qasim MA
    Protein Pept Lett; 2005 Jul; 12(5):465-71. PubMed ID: 16029159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serpin-proteinase complex revealed.
    Lawrence DA
    Nat Struct Biol; 1997 May; 4(5):339-41. PubMed ID: 9145100
    [No Abstract]   [Full Text] [Related]  

  • 18. Divining the serpin inhibition mechanism: a suicide substrate 'springe'?
    Engh RA; Huber R; Bode W; Schulze AJ
    Trends Biotechnol; 1995 Dec; 13(12):503-10. PubMed ID: 8595135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on molecules: maspin.
    Narayan M; Twining S
    Exp Eye Res; 2010 Jan; 90(1):2-3. PubMed ID: 19615364
    [No Abstract]   [Full Text] [Related]  

  • 20. Structural basis for serpin inhibitor activity.
    Wright HT; Scarsdale JN
    Proteins; 1995 Jul; 22(3):210-25. PubMed ID: 7479695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.